Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Prospective Randomized Multicenter Study of Flecainide Acetate Oral Inhalation Solution in Single and Repeat Dose Regimens for Acute Conversion to Sinus Rhythm in Subjects With Recent Onset of Symptomatic Paroxysmal Atrial Fibrillation

Trial Profile

A Prospective Randomized Multicenter Study of Flecainide Acetate Oral Inhalation Solution in Single and Repeat Dose Regimens for Acute Conversion to Sinus Rhythm in Subjects With Recent Onset of Symptomatic Paroxysmal Atrial Fibrillation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jan 2019

At a glance

  • Drugs Flecainide (Primary)
  • Indications Paroxysmal atrial fibrillation
  • Focus Therapeutic Use
  • Acronyms INSTANT
  • Sponsors InCarda Therapeutics
  • Most Recent Events

    • 08 Nov 2018 Planned number of patients changed from 110 to 140.
    • 19 Jun 2018 Status changed from not yet recruiting to recruiting.
    • 01 Jun 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top